［1］Torre LA，Bray F，Siegel RL，et al.Global cancer statistics，2012［J］.CA：A Cancer Journal for Clinicians，2015，65(2)：87-108.
［2］Kanat O，O'Neil BH.Metastatic gastric cancer treatment：A little slow but worthy progress［J］.Medical Oncology，2013，30(1)：1-10.
［3］Huang L，Fu L.Mechanisms of resistance to EGFR tyrosine kinase inhibitors［J］.Acta Pharmaceutica Sinica B，2015，5(5)：390-401.
［4］Lordick F，Kang YK，Chung HC，et al.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND)：A randomised，open-label phase 3 trial［J］.The Lancet Oncology，2013，14(6)：490-499.
［5］Liu X，Guo W，Zhang W，et al.A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer［J］.Bmc Cancer，2017，17(1)：188.
［6］Zhang X，Song Y，Song N，et al.RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src［J］.Oncotargets & Therapy，2017，10：73-83.
［7］Waddell T，Chau I，Cunningham D，et al.Epirubicin，oxaliplatin，and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3)：A randomised，open-label phase 3 trial［J］.The Lancet Oncology，2013，14(6)：481-489.
［8］Tebbutt NC，Price TJ，Ferraro DA，et al.Panitumumab added to docetaxel，cisplatin and fluoropyrimidine in oesophagogastric cancer：ATTAX3 phase II trial［J］.British Journal of Cancer，2016，114(5)：505.
［9］Satoh T，Lee KH，Rha SY，et al.Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer［J］.Gastric Cancer，2015，18(4)：824-832.
［10］Dragovich T，McCoy S，Fenoglio-Preiser CM，et al.Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas：SWOG 0127［J］.J Clin Oncol，2006，24(30)：4922-4927.
［11］Adelstein DJ，Rodriguez CP，Rybicki LA，et al.A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction［J］.Investigational New Drugs，2012，30(4)：1684-1689.
［12］Fanotto V，Ongaro E，Rihawi K，et al.HER-2 inhibition in gastric and colorectal cancers：Tangible achievements，novel acquisitions and future perspectives［J］.Oncotarget，2016，7(42)：69060-69074.
［13］Bang YJ，Van Cutsem E，Feyereislova A，et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)：A phase 3，open-label，randomised controlled trial［J］.The Lancet，2010，376(9742)：687-697.
［14］Thuss-Patience PC，Shah MA，Ohtsu A，et al.Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY)：An international randomised，open-label，adaptive，phase 2/3 study［J］.Lancet Oncology,2017，18：640-653.
［15］Ryu MH，Yoo C，Kim JG，et al.Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer［J］.European Journal of Cancer，2015，51(4)：482-488.
［16］Kurokawa Y，Sugimoto N，Miwa H，et al.Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)［J］.British Journal of Cancer，2014，110(5)：1163-1168.
［17］Kang YK，Shah MA，Ohtsu A，et al.A randomized，open-label，multicenter，adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC)［C］.ASCO Annual Meeting Proceedings，2016，34(4_suppl)：5.
［18］Hecht JR，Bang YJ，Qin SK，et al.Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric，esophageal，or gastroesophageal adenocarcinoma：TRIO-013/LOGIC-A randomized phase III trial［J］.J Clin Oncol，2015，62：6598.
［19］Satoh T，Xu RH，Chung HC，et al.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations：TyTAN-a randomized，phase III study［J］.J Clin Oncol，2014，53：6136.
［20］Janjigian YY，Viola-Villegas N，Holland JP，et al.Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET［J］.Journal of Nuclear Medicine，2013，54(6)：936-943.
［21］Ohtsu A，Shah MA，Van Cutsem E，et al.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer：A randomized，double-blind，placebo-controlled phase III study［J］.J Clin Oncol，2011，36：2236.
［22］Meulendijks D，De Groot JWB，Los M，et al.Bevacizumab combined with docetaxel，oxaliplatin，and capecitabine，followed by maintenance with capecitabine and bevacizumab，as first-line treatment of patients with advanced HER2-negative gastric cancer：A multicenter phase 2 study［J］.Cancer，2016，122(9)：1434-1443.
［23］Fuchs CS，Tomasek J，Yong CJ，et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD)：An international，randomised，multicentre，placebo-controlled，phase 3 trial［J］.The Lancet，2014，383(9911)：31-39.
［24］Wilke H，Muro K，Van Cutsem E，et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW)：A double-blind，randomised phase 3 trial［J］.The Lancet Oncology，2014，15(11)：1224-1235.
［25］Li J，Qin S，Xu J，et al.Randomized，double-blind，placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］.J Clin Oncol，2016，34(13)：1448-1454.
［26］Pavlakis N，Sjoquist KM，Martin AJ，et al.Regorafenib for the treatment of advanced gastric cancer (INTEGRATE)：A multinational placebo-controlled phase II trial［J］.J Clin Oncol，2016，34(23)：2728-2735.
［27］Moehler M，Gepfner-Tuma I，Maderer A，et al.Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus：A randomized，placebo-controlled phase II AIO trial with serum biomarker program［J］.BMC cancer，2016，16(1)：699.
［28］Janjigian YY，Vakiani E，Ku GY，et al.Phase II trial of sorafenib in patients with chemotherapy refractory metastatic esophageal and gastroesophageal (GE) junction cancer［J］.PloS One，2015，10(8)：e0134731.
［29］Riquelme I，Tapia O，Espinoza JA，et al.The Gene expression status of the PI3K/AKT/mTOR pathway in gastric cancer tissues and cell lines［J］.Pathology Oncology Research，2016，22(4)：797-805.
［30］Al-Batran SE，Ducreux M，Ohtsu A.mTOR as a therapeutic target in patients with gastric cancer［J］.International Journal of Cancer，2012，130(3)：491-496.
［31］Ohtsu A，Ajani JA，Bai YX，et al.Everolimus for previously treated advanced gastric cancer：Results of the randomized，double-blind，phase III GRANITE-1 study［J］.J Clin Oncol，2013，31(31)：3935-3943.
［32］Wainberg ZA，Soares HP，Patel R，et al.Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus，gastroesophageal junction and stomach：Possible role for predictive biomarkers［J］.Cancer Chemotherapy and Pharmacology，2015，76(1)：61-67.
［33］Iveson T，Donehower RC，Davidenko I，et al.Rilotumumab in combination with epirubicin，cisplatin，and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma：An open-label，dose de-escalation phase 1b study and a double-blind，randomised phase 2 study［J］.The Lancet Oncology，2014，15(9)：1007-1018.
［34］Cunningham D，Tebbutt NC，Davidenko I，et al.Phase III，randomized，double-blind，multicenter，placebo (P)-controlled trial of rilotumumab (R) plus epirubicin，cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer：RILOMET-1 study［C］.ASCO Annual Meeting Proceedings，2015，33(15_suppl)：4000.
［35］Lennerz JK，Kwak EL，Ackerman A，et al.MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib［J］.J Clin Oncol，2011，29(36)：4803-4810.
［36］Okamoto W，Okamoto I，Arao T，et al.Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification［J］.Molecular Cancer Therapeutics，2012，11(7)：1557-1564.
［37］Kwak EL，LoRusso P，Hamid O，et al.Clinical activity of AMG 337，an oral MET kinase inhibitor，in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ)，gastric (G)，or esophageal (E) cancer［C］.ASCO Annual Meeting Proceedings，2015，33(3_suppl)：1.
［38］Singh P，Toom S，Huang Y.Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer［J］.Journal of Hematology & Oncology，2017，10(1)：105.
［39］Cohen DJ，Liebes L，Xu R，et al.A randomized，double-blind placebo-controlled phase II study of FOLFOX with or without GDC-0449 (vismodegib) in patients with advanced gastric and gastroesophageal junction carcinoma (NCI 8376)［C］.ASCO Annual Meeting Proceedings，2011，29(15_suppl)：TPS173.
［40］Claerhout S，Lim JY，Choi W，et al.Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer［J］.PLoS One，2011，6(9)：e24662.
［41］Yoo C，Ryu MH，Na YS，et al.Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer：Phase II study and biomarker analysis［J］.British Journal of Cancer，2016，114(11)：1185-1190.
［42］Li H，Adachi Y，Yamamoto H，et al.Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line，MKN45［J］.Cancer，2011，117(14)：3135-3147.
［43］Ganguly S，Basu B，Shome S，et al.Dopamine，by acting through its D 2 receptor，inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Krüppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylation［J］.The American Journal of Pathology，2010，177(6)：2701-2707.
［44］Lee KH，Kim JR.Regulation of HGF-mediated cell proliferation and invasion through NF-κB，JunB，and MMP-9 cascades in stomach cancer cells［J］.Clinical & Experimental Metastasis，2012，29(3)：263-272.
［45］Huang W，Yang L，Liang S，et al.AEG-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers［J］.Digestive Diseases and Sciences，2013，58(10)：2873-2880.